U.S. Markets closed

Provectus Biopharmaceuticals, Inc. (PVCT)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0201-0.0080 (-28.4698%)
At close: 3:59PM EDT
People also watch
IMUCNWBOONCSMSTXRNN
Full screen
Previous Close0.0281
Open0.0277
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0200 - 0.0277
52 Week Range0.0110 - 0.2800
Volume4,252,545
Avg. Volume628,157
Market Cap7.44M
Beta0.81
PE Ratio (TTM)-0.22
EPS (TTM)-0.09
Earnings DateMar 31, 2017 - Apr 3, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Trade prices are not sourced from all markets
  • Provectus Biopharmaceuticals Reestablishes Strategic Advisory Board
    PR Newswire4 months ago

    Provectus Biopharmaceuticals Reestablishes Strategic Advisory Board

    KNOXVILLE, Tenn., April 20, 2017 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) ("Provectus" or the "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, today announced the reestablishment of the Company's Strategic Advisory Board (the "SAB"). Initial SAB appointees are John W. 'Jack' Lacey III, M.D., and Ed Pershing as SAB Chairman. Provectus today also announced Mr. Pershing was appointed an observer (serving exclusively in an advisory capacity only) of the Company's board of directors (the "Board"), and Bruce Horowitz was retained as Provectus' chief operations consultant.

  • Provectus Biopharmaceuticals Closes Definitive Financing With PRH Group
    PR Newswire4 months ago

    Provectus Biopharmaceuticals Closes Definitive Financing With PRH Group

    KNOXVILLE, Tenn., April 4, 2017 /PRNewswire/ --  Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) ("Provectus" or the "Company"), a clinical-stage oncology and dermatology biopharmaceutical ...

  • PR Newswire5 months ago

    Provectus Biopharmaceuticals Announces Terms Of Definitive Financing Commitment

    KNOXVILLE, Tenn., March 23, 2017 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com ) ("Provectus" or the "Company"), a clinical-stage oncology and ...